WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010027973) HUMAN PAPILLOMAVIRUS / LI-KEY HYBRIDS AND METHODS OF USE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/027973    International Application No.:    PCT/US2009/055608
Publication Date: 11.03.2010 International Filing Date: 01.09.2009
IPC:
A61K 39/12 (2006.01)
Applicants: ANTIGEN EXPRESS, INC. [US/US]; Biotech Three, 4th Floor One Innovation Drive Worcester, MA 01605 (US) (For All Designated States Except US).
XU, Minzhen [CN/US]; (US) (For US Only).
VON HOFE, Eric [US/US]; (US) (For US Only)
Inventors: XU, Minzhen; (US).
VON HOFE, Eric; (US)
Agent: FARRELL, Kevin, M.; (US)
Priority Data:
61/169,908 16.04.2009 US
61/093,606 02.09.2008 US
Title (EN) HUMAN PAPILLOMAVIRUS / LI-KEY HYBRIDS AND METHODS OF USE
(FR) HYBRIDES DE PAPILLOMAVIRUS HUMAIN/LI-KEY ET LEURS PROCÉDÉS D’UTILISATION
Abstract: front page image
(EN)The present invention is directed towards compositions comprising li-Key / HPV hybrid peptides. The hybrid peptides of the present invention are effective in the generation of CD4+ helper T cell immune responses directed towards the specific HPV epitopes encoded in the hybrid peptide. The inclusion of the li-key peptide in the hybrid causes the peptide to have greater immunogenicity as compared to control peptide. The inclusion of li-Key / HPV hybrid in a peptide vaccine formulation composing both HPV hybrid and HPV CTL epitope peptide (administered concurrently or sequentially) leads to a greater CTL activity against HPV CTL epitopes. The hybrid peptides of the present invention may be useful, for example, for the immunization of subjects against HPV.
(FR)L’invention concerne des compositions comprenant des peptides hybrides li-Key/HPV. Les peptides hybrides de l’invention sont efficaces pour générer des réponses immunitaires des lymphocytes T auxiliaires CD4+ dirigées vers les épitopes spécifiques HPV codés dans le peptide hybride. L’inclusion du peptide li-Key dans l’hybride entraîne une plus grande immunogénécité du peptide par rapport à un peptide témoin. L’inclusion d’un hybride li-Key/HPV dans une formulation de vaccin peptidique composant à la fois un  hybride HPV et un peptide d’épitope HPV CTL (administrés simultanément ou séquentiellement) conduit à une activité CTL plus grande à l’encontre des épitopes HPV CTL. Les peptides hybrides de l’invention peuvent être utilisés, par exemple pour immuniser des sujets contre HPV.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)